Navigation Links
SEC Declares Accuray Form S-4 Registration Statement Effective in Proposed Acquisition of TomoTherapy
Date:5/9/2011

her documents filed by TomoTherapy or Accuray with the SEC, may be obtained free of charge at the SEC's website at www.sec.gov; by contacting Accuray's Investor Relations Department by email at trathjen@accuray.com, by phone at 408.789.4458 or by mail at 1310 Chesapeake Terrace, Sunnyvale, CA 94089, USA; or  by contacting TomoTherapy's Investor Relations Department by email at tpowell@tomotherapy.com by phone at 608.824.2800 or by mail at 1240 Deming Way, Madison, WI 53717-1954 USA.

Participants in the Solicitation

TomoTherapy and its directors and executive officers and other persons may be deemed to be participants in the solicitation of proxies in respect of the proposed transaction.  Information regarding TomoTherapy's directors and executive officers is available in TomoTherapy's proxy statement for its 2010 annual meeting of shareholders and TomoTherapy's Annual Report on Form 10-K for the year ended December 31, 2010, as amended, which were filed with the SEC on March 22, 2010, March 3, 2011, and April 15, 2011, respectively.  Other information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, are contained in the proxy statement and other relevant materials filed with the SEC.

Available Topic Expert(s): For information on the listed expert(s), click appropriate link.

Euan Thomson, Ph.D.

http://profnet.prnewswire.com/Subscriber/ExpertProfile.aspx?ei=81869


'/>"/>
SOURCE Accuray Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
3. Inverness Medical Innovations Declares Dividend on its Series B Convertible Perpetual Preferred Stock
4. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
5. Beckman Coulter Declares Quarterly Dividend Payout of $0.17 Per Share
6. Lilly Declares Fourth-Quarter Dividend
7. Techne Corporation Declares Dividend
8. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
9. Wyeth Declares Preferred Stock Dividend
10. Met-Pro Corporation Declares Quarterly Dividend
11. Schering-Plough Declares Quarterly Dividends on Common Shares and 2007 Mandatory Convertible Preferred Stock
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... YORK , Oct. 20, 2014 ... their experimental ZMapp™ antibody therapeutic to fight the ... how difficult and time-consuming the production of pharmaceuticals ... market research publisher said that while some may ... of this compound, those with industry knowledge are ...
(Date:10/20/2014)... Calif. , Oct. 20, 2014 ... that the Company has signed a Notice of ... Regenerative Medicine (CIRM), effective October 1, 2014.  The ... Development payments and the release of additional grant ... CIRM grant award for clinical development of Asterias, ...
(Date:10/20/2014)... October 20, 2014 , A ... disorders and the delivery of care has revealed changing ... worrying inequalities in the provision of healthcare services across ... commissioned by United European Gastroenterology (UEG), have been announced ... public awareness of the burden of GI disorders across ...
(Date:10/20/2014)... -- PureTech , a science and technology ... announced today the closing of a $55 million ... Perpetual, a $120 Billion group of funds. The ... pipeline forward and to advance new healthcare related ... to really go for the big ideas that ...
Breaking Biology Technology:Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 2Kalorama: ZMapp Highlights Need For Faster Biopharmaceutical Production 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 2Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 3Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 4Major Survey Reveals Changing Trends and Inequalities in Healthcare Provision for Gastrointestinal Disorders Across Europe 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 2PureTech Announces Expansion with Oversubscribed $55M Funding Round 3PureTech Announces Expansion with Oversubscribed $55M Funding Round 4PureTech Announces Expansion with Oversubscribed $55M Funding Round 5PureTech Announces Expansion with Oversubscribed $55M Funding Round 6
... Alseres,Pharmaceuticals, Inc. (Nasdaq: ALSE ) ... President and Chief Business Officer of Alseres,Pharmaceuticals, ... 2nd,Annual Therapeutic Area Partnerships in Philadelphia, PA ... an overview on Alseres Regenerative,Therapeutics program. Cethrin(R), ...
... -- WuXi PharmaTech (NYSE:,WX), China,s premier provider of ... been nominated the winner of Deloitte,Technology Fast 50 ... technology,companies in China as recognized by Deloitte Touche ... The Deloitte Technology Fast 50 China program ...
... 18 Sigma-Aldrich (Nasdaq:,SIAL) announced today the ... System. N-TER allows researchers to reproducibly,interrogate gene ... types that,have previously not been considered amenable ... lipid-based siRNA transfection reagents exhibit a number,of ...
Cached Biology Technology:Alseres Pharmaceuticals, Inc. to Present at Windhover's Therapeutic Area Partnerships Conference 2WuXi PharmaTech (NYSE: WX) Wins Both Deloitte Technology Fast 50 China and Deloitte Technology Fast 500 Asia 2Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2
(Date:10/16/2014)... the bowel lining develops and, in the process, suggested ... The researchers produced evidence that stem cells are responsible ... feature of the bowel lining, and believe these stem ... finding as scientists are still divided on the stem ... Wee Tan and Professor Tony Burgess from the Walter ...
(Date:10/16/2014)... severe respiratory tract infections and worldwide claims the ... VIB and Ghent University have succeeded in developing ... virus infection. , Xavier Saelens (VIB/UGent): "We ... way for the development of a novel approach ... suffering in numerous small children and elderly people." ...
(Date:10/16/2014)... SHELTON, Conn. , October 16, 2014 ... ("NXT-ID" or the "Company"), a biometric authentication company focused ... present its leading edge technologies including Wocket™, the Smart ... Review® (FiRe) Conferenece. FiRe is a leading global conference ... Hosted by Mark Anderson , founder ...
Breaking Biology News(10 mins):Cryptic clues drive new theory of bowel cancer development 2New perspectives for development of an RSV vaccine 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 2NXT-ID Inc. to Present at 13th Annual FiRe Conference 3
... AUSTIN, TexasFrom deep within the genomes of organisms as diverse ... responsible for causing human diseases such as cancer and deafness. ... fact that all life on Earth shares common ancestry, and ... yeast, for example, that humans use to make veins and ...
... for the meeting Experimental Biology 2010 the American ... Society for Biochemistry and Molecular Biology, American Society ... American Society for Pharmacology and Experimental Therapeutics are ... presented April 24-28, at the Anaheim Convention Center. ...
... The general public expects businesses outside the health ... to be involved in health in ways that ... to the Edelman Health Engagement Barometer 2010. Nearly ... that is effectively engaged in health and two-thirds (65 ...
Cached Biology News:Scientists find new genes for cancer, other diseases in plants, yeast and worms 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 2Selected highlights of the research being presented at the Experimental Biology 2010 meeting 3Selected highlights of the research being presented at the Experimental Biology 2010 meeting 4Global study shows 'health' joins 'green' as business strategy 2Global study shows 'health' joins 'green' as business strategy 3Global study shows 'health' joins 'green' as business strategy 4
... the research-grade spectrofluorometer with a minimum 1 ... ratio 200 or greater for the Raman ... designed to keep in mind in order ... stopped-flow, titration, or anisotropic measurements. ,The FP-6500 ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known fish microRNAs ...
... microRNA expression profiling and built on ... on-chip synthesis platform. These microarrays are ... microRNA Expression Profiling Service. ... Microarray contains all known virus microRNAs ...
... extends the legendary MSn performance of the ... information through Thermo Scientifics innovations in ion ... is the only mass spectrometer that offers ... Pulsed Q Collision Induced Dissociation (PQD) ...
Biology Products: